About Boehringer Ingelheim Venture Fund
The Boehringer Ingelheim Venture Fund was formed in
March 2010 to invest in biotechnology and start-up companies to help drive innovation in medical science. These may include - but are not limited to - novel technologies to address so far undrugable targets, new generation vaccines and new biological entities, such as antibody-dependent oncolysis. Novel therapeutic targets and disease-related biomarkers, as well as new approaches in regenerative medicine, are an additional focus.
Through our deep understanding of patients' needs, we develop and provide healthcare in the areas of:
- Behavioral Health and Gastro-Intestinal conditions
- Rare Diseases
- Regenerative Medicine
as well as other symptomatic conditions treated by specialist physicians.
We aspire to imagine and lead the future of healthcare, creating value for patients, physicians, policymakers, payors and our shareholders.
About Takeda Ventures, Inc.
Takeda Ventures, Inc. (TVI) is the corporate venture arm of Takeda Pharmaceutical Company Limited. A wholly owned subsidiary of Takeda America Holdings, Inc., TVI started operations in
and aims to encourage and support therapeutic innovation through early stage capital investment and provision of access to the resources of a multinational pharmaceutical company.
Mitsui & Co. Global Investment, Inc. (MGI
), which has offices in Silicon Valley and
, is a subsidiary of Mitsui & Co. Global Investment Ltd (MGI), which invests in opportunities that have potential for growth. Headquartered in
, MGI has offices in Shanghai,
in addition to MGI
's offices and its investments reach beyond these geographical barriers, reflecting a diversified global portfolio.
SOURCE ArmaGen Technologies, Inc.